Skip to content

A Prospective-Randomized-Controlled Trial of Oral Low-Dose Carvedilol for Transient and Persistent erythema of Erythematotelangiectatic Rosacea

The mechanism of stress-related neuroinflammation in rosacea through HMGB1/TLR2/NF- B signaling pathway Mediated by Ly6Chi cell

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037635
Enrollment
Unknown
Registered
2020-08-29
Start date
2019-05-19
Completion date
Unknown
Last updated
2020-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rosacea

Interventions

Carvedilol group:Oral carvedilol 5mg bid
minocycline group:Oral minocycline 100mg qd

Sponsors

The First Affiliated Hospital of Army Medical University (Southwest Hospital)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. have been diagnosed of ETR with significant facial flushing and erythema but without papulopustular lesions; 3. clinicians Erythema Assessment (CEA) (Table 1) scores >= 2.

Exclusion criteria

Exclusion criteria: 1) Patients who were allergic to carvedilol or minocycline hydrochloride; 2) Patients with bronchial asthma; 3) Patients with hypotension or bradycardia detected by blood pressure monitoring and electrocardiogram; 4) Patients with severe cardiovascular diseases, orthostatic hypotension, cerebral or coronary insufficiency; 5) Patients with severe systemic diseases (myocardial infarction, cardiac failure, cerebral infarction, liver cancer, liver cirrhosis, renal syndrome, acute/chronic renal failure) and hematopoietic disease; 6) Patients with acne, ectopic dermatitis and other facial skin diseases; 7) Pregnant or nursing women and those who plan to become pregnant within one year; 8) Patients who have current drugs, tobacco and alcohol addiction; 9) Patients with malignant tumors, systemic failure or immunodeficiency; 10) Patients who have previously used oral isotretinoin, antibiotics, steroids and other immune suppressants, systemic photochemotherapy, or the use of vasodilators or a-adrenergic receptor-blocking agents in the previous 4 weeks; 11) Patient that have been through topical or laser therapy for rosacea in the previous 4 weeks.

Design outcomes

Primary

MeasureTime frame
Clinician’s Erythema Assessment (CEA);Patient’s Self-Assessment (PSA);

Secondary

MeasureTime frame
The rosacea-specific Qol instrument (RosaQoL);Patient health questionnaire-9 (PHQ-9);Generalized anxiety disorder (GAD-7);Symptom Assessment Form (SAF);

Countries

China

Contacts

Public ContactLi Jian

The First Affiliated Hospital of Army Medical University (Southwest Hospital)

leejian860@126.com+86 15086652137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026